Investors may want to keep an eye on the biotech boom.  

For one, the sector is still one of the safest, most recession-proof investments around.   Two, an aging population is demanding better treatment in an effort to live longer lives. Three, there’s incredible new innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs.  All of which is attracting millions of investors into the red-hot biotech space.

One of the best ways to trade the story is with an ETF, such as the SPDR S&P Biotech ETF (XBI). With an expense ratio of 0.35%, the ETF offers exposure to the S&P Biotechnology Select Industry Index. Some of its top holdings include Biogen, Veracyte, Moderna, Gilead Sciences, Amgen, and VIr Biotechnology to name a few.


Ian Cooper